Searchable abstracts of presentations at key conferences on calcified tissues

ba0001pp331 | Osteoporosis: evaluation and imaging | ECTS2013

May we screen with FRAX clinical factors?

Barbu Carmen Gabriela , Poiana Catalina , Ionita Dariana , Gascan Magda , Stefan Cristina , Stefanopol Aurelia , Fica Simona

Aim: The aim of the study was to evaluate the usefulness of the fracture risk evaluated through the FRAX® model based only on the clinical risk factors as a screening tool for identify the target population for treatment in osteoporosis.Materials and methods: Two hundred and seventy-six postmenopausal women treatment naive referred to two different endocrinology departments for osteoporosis between 2009 and 2011 were evaluated. The FRAX® model ...

ba0007p143 | (1) | ICCBH2019

Intermittent bi-daily sub-cutaneous teriparatide infusion in children with hypoparathyroidism: a single-centre experience

Flammier Sacha , Bertholet-Thomas Aurelia , Tanne Corentin , Bacchetta Justine

Background: Pediatric hypoparathyroidism is an orphan disease. Conventional management combines native and active vitamin D, calcium supplementation and sometimes phosphate binders. The use of teriparatide has been reported both in adults (daily or bi-daily subcutaneous infusions) and in children (rather continuous subcutaneous infusion) as second-line therapy.Methods: We present as median (min-max) the results of a retrospective single-centre review of ...

ba0003pp14 | Arthritis and other joint diseases: translational and clinical | ECTS2014

Effect of risedronate on painful periprosthetic resorption of total hip arthroplasty: preliminary observational study

Behra-Marsac Aurelie , Bonnet Christine , Mabit Christian , Coste Cedric , Preux Pierre-Marie , Vergne-Salle Pascale , Dufauret-Lombard Carine , Treves Richard , Bertin Philippe

Total hip arthroplasty (THA) is the treatment for severe hip osteoarthritis. It improves the quality of life, pain and patient autonomy. However, a periprosthetic resorption may occur, in 3–5% of patients after 10 years of the primary surgery requiring implant replacement. Bisphosphonates (BP), inhibitors of bone resorption, represent a potential candidate for modulating periprosthetic bone loss. Randomized controlled trials have also suggested that BP could prevent early...